What is Puma Biotechnology, Inc.'s (PBYI) StockRank?

MoatMap's StockRank for Puma Biotechnology, Inc. (PBYI) is 98/100, with a Strong Buy signal. This is a composite score combining Quality (85), Value (62), and Momentum (67) factor ranks across MoatMap's universe of 25,000+ stocks.

Does Puma Biotechnology, Inc. have an economic moat?

Puma Biotechnology, Inc. (PBYI) has a Quality factor score of 85/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Puma Biotechnology, Inc. a buy, hold, or sell?

MoatMap's current signal for Puma Biotechnology, Inc. (PBYI) is Strong Buy, based on a StockRank of 98/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.

What sector is Puma Biotechnology, Inc. in?

Puma Biotechnology, Inc. (PBYI) operates in the Healthcare sector, specifically the Biotechnology industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

PBYI

Strong BuyFull HouseFLAG

Puma Biotechnology, Inc. · Healthcare · United States · $468M · Avg Vol: $3M/d

StockRank

Get insider-trade alerts

P/E (TTM)

18.7x

ROE

22.0%

D/E

0.0x

Dividend %

—

AI CONVICTION THESIS

While quantitative eligibility passes, recent insider selling of 0.27% of shares outstanding represents adverse evidence under the provided rubric, requiring a move to FLAG despite the screen eligibility.

COMPANY DESCRIPTION

Puma Biotechnology, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative products for the treatment of cancer. Its lead product, Nerlynx, is approved for certain types of early-stage HER2-positive breast cancer. The company's competitive position is anchored by its approved oncology therapeutic and ongoing clinical development pipeline, operating in the high-stakes pharmaceutical market.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR	TTM
Revenue	228.0M	235.6M	230.5M	228.4M	0.0%	231.2M
EPS	0.00	0.46	0.62	0.62	16.1%	0.51
Shares	46.3M	47.6M	49.1M	50.4M	+8.8%	51.6M
Debt	114.3M	111.5M	74.1M	28.5M	-37.0%	4.8M
Equity	21.6M	53.4M	92.1M	130.3M	82.0%	—
Op CF	-15.8M	27.0M	38.9M	41.8M	24.4%	41.1M
Inv CF	7.1M	-19.1M	-20.4M	-36.2M	—	—
Fin CF	12.2M	0	-33.8M	-45.2M	—	—

Loading 1Y...

PRICE (1Y)+15.0%

SMA 50SMA 200

$9.12

RSI (14)

47.6

52W High

$9.74

From 52W High

0.9%

SCORE BREAKDOWN

Quality

ROIC

25.7%94.7

ROE

22.0%90.3

GP/Assets

80.0%96.1

Op. Margin

13.4%71.1

FCF/Assets

19.3%96.1

Piotroski

783.9

Int. Cover

9.9x61.8

D/E Ratio

0.03x74.8

Current Ratio

2.91x54.3

Value

P/E (TTM)

18.7x63.4

EV/EBITDA

9.9x70.6

P/FCF

11.2x80.3

P/B

3.5x39.9

P/S

2.1x67.2

Div Yield

—N/A

Momentum

52W High %

94%92.4

RS 6M

40%88.4

SMA 50/200

1.20x88.5

EPS Rev 4W

0.0%34.4

EPS Rev 12W

0.0%41.6

EPS Improve

-31%12.7

Q Growth

40%69.9

FUNDAMENTALS

Market Cap

$468M

P/E (Forward)

27.3x

Gross Margin

74.8%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of PBYI are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
PBYI	Puma Biotechnology, Inc.(you)	$468M	98	Strong Buy
CRMD	CorMedix Inc.	$647M	98	Strong Buy
QTTB	Q32 Bio Inc.	$447M	87	Strong Buy
RIGL	Rigel Pharmaceuticals, Inc.	$868M	99	Strong Buy
ZVRA	Zevra Therapeutics, Inc.	$687M	90	Strong Buy
1521.HK	Frontage Holdings Corporation	$310M	90	Strong Buy
PLX	Protalix BioTherapeutics, Inc.	$205M	97	Strong Buy
ABUS	Arbutus Biopharma Corporation	$1.0B	85	Strong Buy
AGEN	Agenus Inc.	$345M	75	Buy
INVA	Innoviva, Inc.	$1.5B	92	Strong Buy

Peer medians: ROE -30.7% · P/E 27.1x · Gross margin 58.1%

Puma Biotechnology, Inc. (PBYI): Stock Score Summary

Puma Biotechnology, Inc. (PBYI) has a MoatMap StockRank of 98/100 based on Quality (85/100), Value (62/100), and Momentum (67/100) factor scores. The current signal is STRONG BUY. While quantitative eligibility passes, recent insider selling of 0.27% of shares outstanding represents adverse evidence under the provided rubric, requiring a move to FLAG despite the screen eligibility.

Key Financial Metrics

Price	$9.12
Market Cap	$468M
P/E (TTM)	18.73
P/E (Forward)	27.29
Price/Book	3.52
Return on Equity	22.0%
Return on Invested Capital	25.7%
Debt/Equity	0.03x
Gross Margin	74.8%
Operating Margin	13.4%
Revenue Growth	7.8%
Free Cash Flow	$42M

Puma Biotechnology, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Puma Biotechnology, Inc.’s (PBYI) StockRank?: MoatMap’s StockRank for Puma Biotechnology, Inc. (PBYI) is 98/100, with a Strong Buy signal. It is a composite of Quality (85), Value (62), and Momentum (67) factor ranks across MoatMap’s universe of 25,000+ stocks.
Does Puma Biotechnology, Inc. have an economic moat?: Puma Biotechnology, Inc. (PBYI) has a Quality factor score of 85/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Puma Biotechnology, Inc. a buy, hold, or sell?: MoatMap’s current signal for Puma Biotechnology, Inc. (PBYI) is Strong Buy, based on a StockRank of 98/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.
What sector is Puma Biotechnology, Inc. in?: Puma Biotechnology, Inc. (PBYI) operates in the Healthcare sector, specifically the Biotechnology industry (United States).